Bano Tasneem, Mohammed Janahi Essam, Dhasmana Anupam, Lohani Mohtashim, Haque Shaful, K Mandal Raju, A Dar Sajad, Jawed Arshad, Wahid Mohd, Akhter Naseem, Y Areeshi Mohammed
Environmental Carcinogenesis and Toxicoinformatics Laboratory, Department of Bioengineering & Biosciences, Integral University, Lucknow, Uttar Pradesh, India.
J BUON. 2018 Sep-Oct;23(5):1514-1527.
The linkage of human T-cell leukemia virus type 1 (HTLV-1) to fatal diseases is a well known fact for many years. However, there has been no significant progress in the field of the treatment that can lead to the development of a successful vaccine. Furthermore, there are no means of assessing the risk of disease and its prognosis in the infected people.
The current study has taken the cognizance of the importance of host's immune response in reducing the risk of infectious diseases to carry out immunoinformatics driven epitope screening strategy of vaccine candidates against HTLV-1. In this study, a genetic variability and HLA distribution analysis among the documented HTLV-1 genotypes I, II, III, IV, V & VI was performed to ensure the coverage of the vast majority of population, where vaccine would be employed. The meticulous screening of effective dominant immunogens was done with the help of ABCPred and Immune Epitope Database.
The results showed that the identified epitopes might be protective immunogens with high conservancy and potential of inducing both protective neutralizing antibodies and T-cell responses. The peptides "PSQLPPTAPPLLPHSNLDHI", "PCPNLVAYSSYHATY", and "YHATYSLYLF", were 100% conserved among different isolates from far and wide separated countries, suggesting negligible antigenic drift in HTLV-1.
Overall, the mentioned epitopes are soluble, non-toxic suitable candidates for the development of vaccine against HTLV-1 and warrant further investigation and experimental validation.
人类1型T细胞白血病病毒（HTLV-1）与致命疾病的关联多年来已是众所周知的事实。然而，在能够促成成功疫苗研发的治疗领域一直没有取得显著进展。此外，目前还没有办法评估感染者的疾病风险及其预后情况。
当前研究认识到宿主免疫反应在降低传染病风险方面的重要性，从而开展了针对HTLV-1的候选疫苗的免疫信息学驱动的表位筛选策略。在本研究中，对已记录的HTLV-1基因型I、II、III、IV、V和VI进行了基因变异性和HLA分布分析，以确保涵盖绝大多数将使用该疫苗的人群。借助ABCPred和免疫表位数据库对有效的显性免疫原进行了细致筛选。
结果表明，所鉴定的表位可能是具有高度保守性且有潜力诱导保护性中和抗体和T细胞反应的保护性免疫原。肽段“PSQLPPTAPPLLPHSNLDHI”、“PCPNLVAYSSYHATY”和“YHATYSLYLF”在来自相距遥远国家的不同分离株中100%保守，这表明HTLV-1的抗原漂移可忽略不计。
总体而言，上述表位是用于研发针对HTLV-1疫苗的可溶、无毒的合适候选物，值得进一步研究和实验验证。
